Amgen Is Said to Agree to Buy Horizon at $26 Billion Value

(December 12, 2022) | By Katie Roof, Michelle F Davis, and Dinesh Nair.

Amgen agrees to pay around $116.5 for each Horizon share

Sanofi, Johnson & Johnson both walked away from discussions

Amgen Inc. has agreed to buy Horizon Therapeutics Plc at a valuation of about $26 billion in what would be its biggest-ever acquisition, according to a person familiar with the matter.

The US biotechnology giant offered around $116.5 for each Horizon share, said the person, who asked not to be identified as the information is private. The offer price is at a around 20% premium to Horizon’s closing price of $97.29 on Friday.